33 results about "High-density lipoprotein" patented technology

The invention relates to a method for constructing a preeclampsia prediction model by using clinical laboratory data and a related application thereof. Specifically, the preeclampsia risk prediction model is constructed based on a plurality of clinical indexes of pregnant women, a plurality of clinical laboratory data and insulin growth binding factor binding protein 1 and / or placental growth factors. The clinical laboratory data comprises leukocyte count and / or urine protein, and further comprises any one or combination of platelet count, monocyte proportion, glutamic-straw / glutamic-pyruvic transaminase ratio, glutamyltranspeptidase, uric acid and high-density lipoprotein. The constructed preeclampsia risk prediction model can provide a reliable implementation means for early prevention and early treatment of preeclampsia. Meanwhile, the sensitivity of the prediction model is 88.0% when the specificity of early eclampsia is 85.04% and the sensitivity of the prediction model is 62.5% when the specificity of late eclampsia is 85.04% in a complete independent verification set, and the detection performance of the prediction model is higher than that of the current detection performance.

The invention relates to the technical field of anti-tumor bionic nanomaterials, and discloses a preparation method and application of tumor-bacterial membrane chimeric nanoparticles, and the preparation method comprises the following steps: carrying out rotary evaporation on dimyristoyl phosphatidylcholine and cholesterol oleate to obtain an HDL rotary evaporation film; mixing the tumor cell membrane with the bacterial membrane to obtain a tumor-bacterial mixed membrane; pre-mixing apolipoprotein ApoA-1 with the tumor-bacteria mixed membrane, and adding the mixed solution into a container containing an HDL rotary evaporation membrane for hydration and reconstruction to obtain a crude suspension; and carrying out ultrafiltration purification on the crude suspension to obtain the tumor-bacterial membrane chimeric nanoparticles. The tumor cell membrane and the bacterial membrane are co-loaded on the high-density lipoprotein, so that the two membrane components can be co-delivered to the dendritic cells to induce maturation of the dendritic cells, are accumulated in tumors and drainage lymph nodes in vivo, activate CD8 + T cell response and have an inhibition effect on tumor growth.

The invention discloses a novel application of emodin and a high-density lipoprotein analogue in preparation of a medicine. The high-density lipoprotein analogue comprises apolipoprotein A-1 single mimetic peptide and natural phospholipid. The invention has the advantages of long-term stability and no immunogenicity and organ toxicity risk, thereby providing a clinically convertible solution for precise treatment of nerve injury.

Provided are molecular hooks that are capable of tethering a protein of interest to a high-density lipoprotein (HDL) molecule. Also provided are methods of intracellular protein delivery to cells and organisms using the molecular hooks of the present disclosure. Such methods provide several advantages including the ability to intracellularly deliver the protein of interest to tissues behind the blood-brain barrier, and not requiring extreme cold temperatures for storage or transport.

The invention provides pediococcus acidilactici XZFMCC101.23156, a microbial preparation, an antibacterial composition and application of the pediococcus acidilactici XZFMCC101.23156, and belongs to the technical field of functional microorganisms. The preservation number of the pediococcus acidilactici XZFMCC101.23156 is GDMCC No: 66860, and the pediococcus acidilactici XZFMCC101.23156 can be used as a functional microbial agent to be applied in vivo to improve diseases such as hyperlipidemia and the like, and can also achieve the effect of reducing body weight. The result of the embodiment shows that the culture supernatant of the pediococcus acidilactici XZFMCC101.23156 can effectively reduce the total cholesterol, the triglyceride, the low-density lipoprotein and the high-density lipoprotein in a rat body. The pediococcus acidilactici XZFMCC101.23156 provides a new way for the development of oral probiotic preparations and the preparation of foods, drinks, health care products and medicines with the function of degrading cholesterol.

The present invention is related to the field of targeted drug delivery. In particular, the particles and compositions described herein are used to deliver drugs to treat the diseases and conditions of interest. These particles and compositions include, but are not limited to, the lipopeptide complexes that mimic human high-density lipoproteins but contain apolipoprotein fragments or combination thereof.

Conventionally, it has been necessary to collect blood of a subject and perform biochemical analysis to measure LDL cholesterol and HDL cholesterol. However, in this method, a needle or the like needs to be invasively inserted into the skin of the subject, which causes a psychological or physical burden on the subject. According to the present invention, it is possible to non-invasively estimate cholesterol based on attribute information and / or non-invasive biological information of a predetermined user by generating a cholesterol estimation model by machine learning based on attribute information, non-invasive biological information, and blood examination data acquired from a plurality of subjects in advance.

The present invention relates to obeticholic acid:or a pharmaceutically acceptable salt, solvate or amino acid conjugate thereof. Obeticholic acid is useful for the treatment or prevention of a FXR mediated disease or condition, cardiovascular disease or cholestatic liver disease, and for reducing HDL cholesterol, for lowering triglycerides in a mammal, or for inhibition of fibrosis. The present invention also relates to processes for the synthesis of obeticholic acid.

The invention discloses a polysaccharide composition for treating chronic alcoholic liver injury and application thereof, and belongs to the field of biological medicine. The polysaccharide composition is prepared by crushing phellinus linteus linteus, bolete, morchella and cordyceps militaris, mixing the crushed materials according to a mass ratio of 4: 2: 2: 2, performing water ultrasonic extraction, and performing hot water extraction. The polysaccharide composition can reduce fat vacuolation and hepatocyte swelling in the liver, inhibit expression of liver function related enzymes such as ALT and AST, improve secretion of blood fat such as total cholesterol, triglyceride and high-density lipoprotein cholesterol and reduce expression of inflammatory factors such as IL-1beta and TNF-alpha in the liver, and the effect of the polysaccharide composition is better than that of single polysaccharide. The polysaccharide composition can relieve liver injury caused by long-term drinking and achieve the effects of dispelling the effects of alcohol and protecting the liver.

The invention relates to pegylated recombinant high-density lipoprotein nanoparticles, which have the effect of preventing or treating neurodegenerative diseases. Specifically, the present invention relates to a nanoparticle and a method for preparing the same, in which a polyethylene glycol-lipid (PEG-lipid) or a derivative thereof is added during the preparation of a fluid containing a hydrophobic substance and a fluid containing a hydrophilic substance, thereby protecting a phospholipid layer of the prepared nanoparticle by PEG, and to a method for preparing the same. The pegylated nanoparticles not only maintain the original blood-brain barrier-crossing delivery ability, but also have the ability to avoid a clearance mechanism caused by in-vivo immune action, thus having excellent stability, and exhibiting a long-term pharmacological effect on the basis of the high in-vivo circulation ability thereof. Therefore, the compound can be effectively used as a drug or a drug delivery vehicle.

The invention discloses a lactobacillus plantarum BH52, which has a preservation number of CCTCC (China Center for Type Culture Collection) NO: M 20251294, and is characterized in that the preservation number of the lactobacillus plantarum BH52 is CCTCC NO: M 20251294. The strain is separated from human intestinal tracts, and is identified as plant lactobacillus through 16S rRNA (ribosomal Ribonucleic Acid) sequencing. Experiments show that the BH52 strain can efficiently degrade cholesterol and uric acid, significantly increase high density lipoprotein (HDL is increased by 29.8%), and improve kidney function indexes. The gastric acid resistance (the survival rate is 91.5% when the pH value is 3.0) and the cholate resistance (the survival rate is 94.3% when the cholate is 0.3%) are excellent, and the safety is high. The strain can be independently used or compounded for preparing functional foods or medicines for reducing blood fat and uric acid.

The application discloses a method for constructing a hyperlipidemia-resistant rat model, and belongs to the technical field of experimental animal model construction. S1, basic population screening: abnormal lipid metabolism rats are selected, and the rats are fed with high-fat feed at the age of 4 weeks, and the feeding is continuously performed for 4 weeks; S2, blood lipid detection and preliminary screening: the animals are fasted for 12h, blood is taken from the submandibular vein, serum is separated by centrifugation at 3000r / min for 10min, and the total cholesterol, triglyceride, high-density lipoprotein cholesterol and low-density lipoprotein cholesterol contents are detected by using an automatic biochemical analyzer; S3, paired reproduction and subculture: 30 male rats and 30 female rats are selected, and the rats are paired for reproduction at a ratio of 1:1 to obtain F1 generation; S4, inbreeding and stabilization: the F2-F4 generation rats are repeatedly fed, detected, screened and paired for reproduction according to steps S1-S3, and the F4 generation hyperlipidemia-resistant rat model is obtained through inbreeding, and the technical effect of obtaining the hyperlipidemia-resistant rat model which is stable in phenotype and can be inherited and subcultured is achieved through the combination of hybridization screening and inbreeding.

The present invention relates to: reconstituted high-density lipoprotein nanoparticles comprising cholesterol; and a composition for preventing or treating Alzheimer's disease and cancer, the composition comprising the nanoparticles. Specifically, the reconstituted high-density lipoprotein nanoparticles comprising cholesterol according to the present invention have an excellent cell influx rate and promote cholesterol efflux from cells, thus having a cancer cell killing effect, and can therefore be used for preventing or treating cancer.

The present application belongs to the technical field of medical risk assessment, and proposes a fibrosis metabolism related fatty hepatitis risk assessment system. It comprises: a data acquisition module configured to determine candidate prediction indicators; a primary screening module configured to perform single-factor logistic regression analysis on the candidate prediction indicators to determine key prediction indicators of fibrosis metabolism related fatty hepatitis; a secondary screening module configured to screen four independent prediction factors from the key prediction indicators of fibrosis metabolism related fatty hepatitis through stepwise multiple regression analysis; and a model training module configured to train a constructed multi-factor logistic regression model based on the four screened independent prediction factors. The present application integrates four indicators of aspartate aminotransferase, alanine aminotransferase, triglyceride and high-density lipoprotein cholesterol to construct a fibrosis MASH evaluation prediction model for obese people, which has better evaluation performance.

A herbal composition for the treatment of a variety of metabolic disorders in mammals, especially human beings, is disclosed. A method of preparing the herbal composition is also disclosed. The herbal composition treats and alleviates a plurality of metabolic disorders, including central obesity, high blood pressure levels, high blood sugar levels, stress-induced fatigue, and type 2 diabetes. The herbal composition comprises the extracts of Dolichos lablab, Achyranthes aspera, and at least one of Cinnamomum zeylanicum and Cinnamomum cassia. The aforementioned extracts are present in the herbal composition at a predetermined weight range. The aforementioned extracts are standardized to contain active compounds, including proanthocyanidins, saponins, polyphenols, and tannins, in a predetermined concentration and in predetermined purity levels. The herbal composition causes an enhancement of adiponectin levels and high-density lipoprotein (HDL) levels, and a reduction in the accumulation of adipose tissue, total cholesterol levels, triglyceride levels, and low-density lipoprotein (LDL) levels.

A method for constructing a preeclampsia prediction model by using clinical laboratory data and the use thereof. Specifically, the preeclampsia risk prediction model is constructed on the basis of several clinical indexes of pregnant women, several pieces of clinical laboratory data, and insulin-like growth factor-binding protein 1 and / or placental growth factor. The several pieces of clinical laboratory data comprise white blood cell count and / or urine protein, and further comprise any one or a combination of platelet count, monocyte percentage, aspartate aminotransferase / alanine aminotransferase ratio, glutamyl transpeptidase, uric acid and high-density lipoprotein. The constructed preeclampsia risk prediction model can provide a reliable implementation means for early prevention and early treatment of preeclampsia. Moreover, in a fully independent validation set, when the specificity of the prediction model for early-onset preeclampsia is 85.04%, the sensitivity is 88.0%, and when the specificity for late-onset preeclampsia is 85.04%, the sensitivity is 62.5%, outperforming the current detection performance.

The application belongs to the field of biological medicine research and development, and particularly relates to application of umbilical cord mesenchymal stem cell-derived vascular endothelial precursor cells in preparation of medicines for preventing and treating atherosclerosis. By interfering with expression of related factors in a pyroptosis inflammatory signaling pathway of NLRP3, ASC, Caspase-1, GSDMD, IL-1β and IL-18 at a transcription and protein level, the serum triglyceride concentration, total cholesterol concentration and low-density lipoprotein concentration can be reduced, the serum oxidized low-density lipoprotein and oxygen free radical concentration can be reduced, the serum high-density lipoprotein concentration can be increased, and the atherosclerotic plaque area can be reduced and cell apoptosis in the atheromatous plaque can be inhibited.

The invention belongs to the technical field of traditional Chinese medicines, and discloses a traditional Chinese medicine preparation for treating metabolic syndrome, which is prepared from the following raw material medicines in parts by weight: 10-20 parts of lotus leaf, 5-15 parts of hawthorn, 5-15 parts of salvia miltiorrhiza, 10-20 parts of cassia seed, 5-15 parts of chrysanthemum, 20-40 parts of corn stigma, 5-15 parts of mulberry leaf, 10-20 parts of poria cocos, 5-15 parts of rhizoma alismatis, 5-15 parts of burdock root, 15-25 parts of fried radish seed and 20-40 parts of raw malt. According to the traditional Chinese medicine composition, heat clearing, diuresis promoting, digestion promoting and stagnation removing are adopted as methods, and the effects of heat clearing, diuresis promoting, digestion promoting and stagnation removing and blood circulation promoting and blood stasis removing are achieved through combination of all the medicine materials for the damp-heat accumulation type metabolic syndrome. Clinical research shows that the total effective rate of the traditional Chinese medicine composition is 75.93% when the traditional Chinese medicine composition is combined with conventional western medicines to treat the metabolic syndrome and is remarkably superior to that of a pure western medicine control group (53.70%); the blood pressure, the body mass index, the waist-hip ratio, the fasting blood glucose, the fasting insulin, the insulin resistance index and the blood fat level of a patient can be remarkably reduced, the high-density lipoprotein cholesterol can be increased, and obvious adverse effects are avoided. The traditional Chinese medicine composition is precise and appropriate in formula, exact in curative effect and high in safety, and has a good clinical application prospect.

PEGylated reconstituted high-density lipoprotein nanoparticles having the effect of preventing or treating neurodegenerative diseases are provided. Specifically, the present invention relates to nanoparticles and a method for producing the same, a phospholipid layer of the produced nanoparticles being protected by PEG due to PEG-lipid or a derivative thereof being included in the process of preparing a fluid comprising a hydrophobic material and a fluid comprising a hydrophilic material. The PEGylated nanoparticles have the ability to avoid the rejection mechanism of the immune response in the body while maintaining the existing transport ability across the blood-brain barrier, thereby having excellent stability and exhibiting long-term pharmacological effect due to high circulation ability in the body, and thus can be effectively utilized as a drug or a drug carrier.

This invention discloses a probe for detecting Ox-LDL and its applications, belonging to the field of Ox-LDL detection technology. This invention provides a variety of probe molecules that can specifically and sensitively recognize Ox-LDL and effectively distinguish between high-density lipoprotein (HDL), low-density lipoprotein (LDL), and Ox-LDL. The probe exhibits significantly enhanced fluorescence in the presence of Ox-LDL, while showing almost no fluorescence in pure PBS solution, with low background noise. The probe of this invention is a molecular probe, simple to prepare, stable, easy to store and detect, and can be used as a reagent for detecting Ox-LDL in peripheral blood, cells, and tissues, a lipoprotein identification reagent, an early diagnostic reagent for atherosclerosis, and an early diagnostic reagent for fatty liver.

1. Name of the product in this design: Blood Lipid Analyzer. 2. Purpose of this design: For self-testing of four lipid parameters (total cholesterol, triglycerides, high-density lipoprotein, and low-density lipoprotein) by patients with hyperlipidemia or for bedside testing in medical institutions. 3. The key design features of this product are: the main view. 4. The image or photograph that best illustrates the design's key features: the front view.

This invention discloses a traditional Chinese medicine composition for treating non-alcoholic fatty liver disease (NAFLD). The composition is made from the following raw materials in parts by weight: 12 parts turmeric extract, 9 parts rhubarb extract, 10 parts atractylodes macrocephala extract, 10 parts gynostemma pentaphyllum extract, 10 parts kudzu root extract, 10 parts lotus leaf extract, 10 parts alisma plantago-aquatica extract, 10 parts salvia miltiorrhiza extract, 15 parts polygonum cuspidatum extract, 10 parts silkworm extract, 3 parts leech extract, 10 parts malachite extract, and 6 parts licorice extract; as well as its preparation method and uses. This composition can effectively alleviate the clinical symptoms of NAFLD patients, improve liver function, reduce the levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transferase (GGT), and triglycerides (TG), total cholesterol (TC), and low-density lipoprotein (LDL-C) in the blood, and increase the level of high-density lipoprotein (HDL-C), effectively improving blood lipids and alleviating the protracted disease progression towards recovery.

The invention belongs to the technical field of medicines, and particularly relates to a composition for preventing and treating children obesity and a preparation method thereof. The composition comprises the following raw materials in parts by weight: 35-45 parts of active pharmaceutical ingredients and 8-15 parts of auxiliary materials, the active pharmaceutical ingredient is composed of sipunculus nudus polypeptide and catalpa glycoside in a mass ratio of 1: (1.5-3). The composition can inhibit the weight gain of mice with high fat diet, reduce the total cholesterol, triglyceride and low-density lipoprotein level in serum of the mice, and improve the high-density lipoprotein level in the serum. In addition, the composition can also improve liver fat accumulation and relieve fatty liver lesion caused by liver fat accumulation, and has no influence on renal functions.

The invention relates to a traditional Chinese medicine composition for improving blood lipid metabolism disorder and application thereof. The traditional Chinese medicine composition for improving blood lipid metabolism disorder is prepared from the following traditional Chinese medicine components: rhizoma atractylodis macrocephalae, Chinese yam, herba cistanche, fructus amomi rotundus, radix salviae miltiorrhizae, raw radix et rhizoma rhei and radix glycyrrhizae preparata. According to the traditional Chinese medicine composition provided by the invention, the rhizoma atractylodis macrocephalae, the Chinese yam, the cistanche, the amomum cardamomum, the salvia miltiorrhiza, the raw rhubarb and the honey-fried licorice root are compatible, and all the components are mutually matched and have a synergistic effect, so that the traditional Chinese medicine composition has an excellent effect of improving the blood lipid metabolism disorder; specifically, the composition can improve the level of high-density lipoprotein in serum and / or reduce the level of low-density lipoprotein in serum, and the effects are obviously superior to those of a'spleen-tonifying and kidney-tonifying prescription '.

A method of assessing the risk for development of cardiovascular disease (CVD) or an inflammatory disease in a patient comprises (i) incubating a sample of body fluid with donor particles, wherein the donor particles are coated with a lipid and a first quantity of detectably labeled, non-exchangeable lipid probe (NELP); (ii) separating the detectably labeled NELP-associated HDL into a first portion and the donor particles into a second portion; (iii) measuring the second quantity of detectably labeled NELP in the first portion; (iv) determining a detectably labeled NELP efflux value for the patient; and (v) comparing the detectably labeled NELP efflux value for the patient to a reference standard. Related methods of lowering the risk for development of CVD or an inflammatory disease in a patient and methods of measuring the quantity of functional HDL in a sample of body fluid are also provided.

The application discloses a health wine with the functions of reducing triglyceride, total cholesterol and blood pressure and a preparation method thereof. Red highland corn and bitter buckwheat are used as fermentation raw materials, and base wine is obtained through saccharification and distillation. The core of the method is that the residue of the raw material after distillation is subjected to two solid-state fermentations, and the ultrasonic-assisted extraction and percolation extraction technologies are combined to efficiently extract an extract liquid rich in active ingredients, which is accurately added into the base wine after concentration and freeze-drying. The method realizes multi-level utilization of the raw material, and significantly improves the extraction rate of functional components such as flavonoids and polysaccharides. The active ingredients in the product are added simultaneously, and the polysaccharides in pilose antler and the active ingredients in bitter buckwheat are synergistically enhanced. Animal experiments show that the health wine has the functions of reducing blood sugar, blood fat and blood pressure.

The invention relates to the technical field of biochemical detection, and discloses a dry chemical test paper for quantitative determination of human whole blood high density lipoprotein cholesterol content, which comprises a diffusion layer, a blood filter layer, a pre-precipitation layer, a precipitation layer, a supplementary precipitation layer and a reaction layer which are sequentially stacked from top to bottom, the pre-precipitation layer is coated with a first reagent, the first reagent contains a precipitant I, the precipitation layer is coated with a second reagent, the second reagent contains a precipitant II, the supplementary precipitation layer is coated with a third reagent, and the third reagent contains a precipitant III; the precipitant I, the precipitant II and the precipitant III respectively adopt at least one of dextran sulfate, polyethylene glycol 2000, phosphotungstic acid and polyethyleneimine, and the precipitant I, the precipitant II and the precipitant III adopt different formulas. The dry chemical test paper can realize simple, rapid, high-precision and high-accuracy quantitative determination of high-density lipoprotein cholesterol in human whole blood, and solves the technical problems of low detection accuracy and precision of existing dry chemical test paper.

1. Name of the product in this design: Blood Lipid Detection Card. 2. Purpose of this design: For the analysis and detection of total cholesterol, triglycerides and high-density lipoprotein cholesterol in whole blood or serum. 3. The key design feature of this product is its shape. 4. The image or photograph that best illustrates the design's key points: 3D view 1.

The application discloses the technical field of lipid-lowering tea, and discloses a compound lipid-lowering tea and a preparation method thereof.The compound lipid-lowering tea comprises 10g of cassia seed, 5-15g of gynostemma pentaphyllum, 5-15g of salvia miltiorrhiza, 5-15g of hawthorn and 5-15g of bidens pilosa.The lipid-lowering active ingredients in medicinal materials, such as tanshinone, flavone, ursolic acid and anthraquinone, are studied, and it is clear that these ingredients play a lipid-lowering role through multiple signal pathways, such as the PI3K-AKT signal pathway, the cancer pathogenesis pathway and the estrogen signal pathway.Among them, the flavone is combined with the core target point PPARG, the anthraquinone is combined with HSP90AA, the ursolic acid is combined with ESR1, the lipid synthesis and metabolism are regulated, the fat index, the serum low-density lipoprotein and the triglyceride level are reduced, and the synthesis of high-density lipoprotein is promoted.The animal experiment verifies that the lipid-lowering tea has a significant lipid-lowering effect, and has no adverse effect on the organs of mice, thereby providing a new safe and effective lipid-lowering option for patients with hyperlipidemia.

The present application relates to a kind of traditional Chinese medicine compositions, including the following weight parts of preparation raw materials: Huanglian 15~20 parts, Fashi 15~18 parts, Gualoupi 30~45 parts, Juhong 10~15 parts, Danshen 15~20 parts, Baishu 15~20 parts.The traditional Chinese medicine composition prepared in the present application has obvious effect of resisting non-alcoholic fatty liver disease (NAFLD), compared with Rosuvastatin, can further improve the lipid accumulation and balloon-like change of liver, improve the level of triglyceride (TG), cholesterol (TC), low-density lipoprotein (LDL-C) and high-density lipoprotein (HDL-C) in blood fat, reduce liver damage index glutamic-pyruvic transaminase (ALT), inhibit the expression of inflammatory factors (TNF-alpha and IL-1beta).At the same time, the body weight of NAFLD mouse can be significantly reduced, glucose tolerance can be improved, insulin sensitivity can be improved, insulin resistance can be reduced, and the efficacy of regulating intestinal flora and increasing the abundance of intestinal Akkermansia bacteria can be achieved.